Eagle Pharmaceuticals
50 Tice Blvd, Suite 315
Woodcliffe Lake
New Jersey
07677
United States
Tel: (201) 326-5300
Website: https://www.eagleus.com/
288 articles about Eagle Pharmaceuticals
-
Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker
1/31/2022
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, (“AOP Health”), with whom it entered into a licensing agreement in August 2021, has engaged with the U.S. Food and Drug Administration (“FDA”) to obtain alignment on the content and format of the pre-clinical and clinical data required to support a new drug application (“NDA”) seeking approval of Landiolol.
-
Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin
1/18/2022
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict with 180 days of marketing exclusivity.
-
Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin
1/5/2022
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update for 2022:
-
Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference as follows.
-
Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin
12/29/2021
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application (“ANDA”) for vasopressin.
-
Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin
12/20/2021
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.
-
Eagle Pharmaceuticals Receives FDA Approval for Vasopressin
12/15/2021
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company’s abbreviated new drug application (“ANDA”) for vasopressin.
-
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
11/22/2021
Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
-
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
11/9/2021
Eagle Pharmaceuticals Reports Third Quarter 2021 Results
-
Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021
10/28/2021
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens.
-
Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021
9/7/2021
Eagle Pharmaceuticals, Inc. will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:.
-
Eagle Pharmaceuticals to Present at September Healthcare Conferences
9/1/2021
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences.
-
Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise
8/31/2021
Eagle Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled “Formulations of Bendamustine.” Eagle is submitting the ‘483 patent for listing in the U.S. Food and Drug Administration’s Orange Book for both BENDEKA® and BELRAPZO®.
-
Eagle Pharmaceuticals Wins Vasopressin Patent Trial
8/31/2021
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against the Company.
-
Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
8/25/2021
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA
-
Eagle Pharmaceuticals Reports Second Quarter 2021 Results
8/9/2021
Eagle Pharmaceuticals, Inc. announced financial results for the three and six months ended June 30, 2021.
-
Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker
8/9/2021
Eagle Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH, a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States.
-
Eagle Pharmaceuticals to Host Second Quarter 2021 Financial Results on August 9, 2021
7/28/2021
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens.
-
Eagle Pharmaceuticals Announces FDA Maintains Prioritization of ANDA for Vasopressin
6/24/2021
Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug and Administration has maintained Priority Review for the Company’s Abbreviated New Drug Application for vasopressin.
-
Eagle Pharmaceuticals Submits Response to Complete Response Letter from FDA for Vasopressin
6/17/2021
Eagle Pharmaceuticals, Inc. announced that it has responded to the Complete Response Letter for its Abbreviated New Drug Application for vasopressin received from the U.S. Food and Drug Administration in February 2021.